The total revenue from operations was up by 27 per cent to Rs 6,770 crore as against Rs 5,319.7 crore, in the corresponding quarter in 2021, Hyderabad-based pharmaceutical giant said in a release here.
For the first nine-months ended December, 2022, the Pharma’s net profit rose by 56 percent to Rs 3,548 crore while revenues increased by 14 per cent to Rs 18,291 crore.
Commenting on the results, Co-chairman and Managing Director, G V Prasad said “Our strong financial performance was supported by growth in the US and the Russia markets.
He said we continue to strengthen our development pipeline to reach more patients globally.”
(With UNI inputs)